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Guiding neurons, and guiding scientists
Marc Tessier-Lavigne’s career has straddled academia and industry, and
blurred traditional boundaries between basic and translational science
by ZACH VEILLEUX

Making
Rockefeller my
new home
I am honored and delighted to be
joining the university on March
16. The past six months have
been a busy and exciting period of
preparation — for my family and
my lab as well as for me personally
— as we planned our move to New
York. Over these months I have
had the opportunity to meet many
of the faculty, students, administration and staff, and the excitement I
felt on my appointment as president has only grown during that
time.
On Monday, March 21, I will
hold a town hall meeting for all
members of the campus community
at 3 p.m. in Caspary Auditorium
to discuss my initial priorities, to
answer any and all questions you
might have, and to set the stage
for the strategic planning we will
be embarking on collectively in
subsequent months.
I very much look forward to
meeting many more of the community in the near future, and to
becoming part of the university,
making it my home both personally
and professionally.

Marc Tessier-Lavigne’s journey into neuroscience began a few hundred miles off the
coast of Newfoundland, aboard the Queen
Elizabeth II. It was 1980, and Dr. TessierLavigne, then 20 years old, was headed to
Oxford University with plans to pursue a
Ph.D. in physics.
Physics wasn’t quite what he’d envisioned doing as a child, but it was close.
Growing up, Dr. Tessier-Lavigne was
certain he would become a mathematician,
something he loved and excelled at in the
French schools he attended while his father,
a member of the Canadian Armed Forces,
was posted to Europe. In college, at McGill
University, he became focused on physics,
and wrote his undergraduate thesis on the
biophysics of blood flow.
But it was the five-day crossing to the
U.K. — the Rhodes Scholarship he had
secured to attend Oxford came with a free
transatlantic cruise — that caused him to
rethink those plans.
“During those restful days of contemplation on the ocean, I began to realize there
was much I still wanted to explore before
locking myself in to a specialty,” Dr. TessierLavigne recalls. “While leafing through the
thick book of Oxford’s courses of study, I
decided to put my plans for an advanced
degree on hold and instead pursue a second
bachelor’s.” The Rhodes Scholarships do not
put any restrictions on field of study, and so
by the time the ship docked in Southampton, his new course was set.
The program he chose to pursue was
called Philosophy, Psychology and Physiology. Normally, students study all three in
their first year, then select two to specialize
in for their final two years. Dr. TessierLavigne, whose previous undergrad credits
allowed him to skip the first year, immediately chose philosophy and physiology —
by far the least popular of the permutations.
“It was an odd combination, but it

turned out to be the perfect course of study
for me,” he says. “It taught me logic and
constructive skepticism and gave me my
first exposure to neuroscience, which I
immediately fell in love with. The brain is
the most complex and fascinating organ in
the body, and the thought that one could
deconstruct and resolve that complexity
was thrilling. My career was set.”
In 1983, Dr. Tessier-Lavigne moved
down the road to London, where he would
spend the next four years, his Ph.D. training,
at a University College London lab bench
performing electrical recordings from neural
cells in slices of retinal tissue from the back
of the eye. His training in physics proved
useful in his work to understand how neural
circuits processed information, but his
curiosity soon led him to wonder how such
circuits develop and form connections and,
ultimately, how they alter those connections
throughout life as a result of experience.
It was these fundamental questions of
neuroscience that would drive Dr. TessierLavigne’s work for the next three decades.
Moving to the States for postdoctoral
work at Columbia University, he sought
to understand the molecular cues that are
involved in guiding a developing neuron’s
tendril-like axons through the body to
connect with an appropriate target cell. He
and his colleagues developed simple models
of specific path-finding events in a Petri
dish, and used the preparations to demonstrate the existence of chemoattractive
activity for axon tips in the spinal cord.
A few years later, as a junior faculty
member at the University of California at
San Francisco, he made a name for himself
by discovering the molecular identity of this
chemoattractive factor, now called netrin. It
was a high-risk project involving brute-force
biochemistry and the brains of more than
25,000 chicken embryos, but it answered a
question that had stumped neurobiologists

To understand the brain, Tessier-Lavigne studies its wiring
It takes several hundred billion nerve cells
to put together the human brain, and they
must be connected in an intricate and precise
pattern in order to function properly. The
formation of these connections — the brain’s
neural circuits — during an organism’s
embryonic development is what ultimately
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allows the brain to perceive, remember and
of California at San Francisco — was that
issue commands to the rest of the body.
of netrins, a small family of proteins presSince he first encountered neuroscient in the axon’s environment that interact
ence as a student at Oxford University,
with receptors on the growth cone in order
Marc Tessier-Lavigne has been
fascinated with the formation of
these neural circuits, and he has
devoted his scientific career to
understanding how nerve cells
figure out where to go.
The key to this process of
“neuronal guidance” is the axon,
a slender extension to the neuron
that seeks out and connects to
the appropriate set of target cells.
Neurons and netrin. Results from an early neuronal guidance
experiment show the growth of long finger-like bundles of
The tip of each developing axon
axons from neural tissue cultured with netrin (right) compared
contains a specialized sensory
to tissue grown without. Dr. Tessier-Lavigne published these
structure called the growth cone,
images in Cell in 1994.
which senses chemical guidance
cues that instruct it to migrate in
a particular direction. Until the early ’90s,
to steer the developing brain cells. The
that was all anyone knew. But Dr. Tessierdiscovery of netrins was published in two
Lavigne’s key discovery — made when he
Cell papers in August 1994.
was an assistant professor at the University
continued on page 2

for over a century, and it launched a new
era of discovery in the neurosciences. Techniques and knowledge developed during the
search for netrin have since been used — by
Dr. Tessier-Lavigne and other labs around
the world — to determine the identities of
other guidance factors and better understand the neural wiring code that underlies
the structure of the human brain and nervous system. The work also had potentially
ground-breaking medical applications.
“Insights into axon growth and guidance during development have important
implications for attempts to stimulate axon
regeneration following injury in the adult
nervous system,” Dr. Tessier-Lavigne says.
“The development of drugs based on guidance factors like netrin has the potential
to stimulate regeneration of nerve fibers
following paralyzing spinal cord injuries.”
The possibility of creating such drugs
was tantalizing, and so starting in the late
’90s, while still at UCSF, Dr. Tessier-Lavigne
also became involved in a number of biotech
ventures focused on bringing neurologic
therapeutics to market. He served on several
scientific advisory boards and cofounded a
company, Renovis, Inc., devoted to treatments for neuroprotection, pain and neurodegenerative diseases. Moonlighting in the
private sector turned out to suit him well.
“I was quite excited about what could
be accomplished in industry, which has
different strengths than academia,” he
continued on page 2

FROM RUSS CARSON

Welcoming the
Tessier-Lavignes
As chairman of the Board of
Trustees it is my great honor and
pleasure to welcome Marc TessierLavigne as our 10th president.
Through my role as chairman
of the search committee that hired
Marc, and through my frequent
interactions with him since then, I
can assure you that he is the right
choice at the right time. Of the candidates we interviewed for the job,
Marc had the best balance of being
both a highly accomplished scientist
and a proven administrator.
His prior experiences at UCSF,
Stanford and Genentech have
prepared him well for taking on the
responsibilities of leading our university. Many of you have had the
opportunity to witness Marc’s energy and interpersonal skills; those
who have not are in for a treat.
My fellow trustees and I are delighted that he chose to accept our
offer and we look forward to a long
and fruitful relationship with both
Marc and his wife Mary.

Neuroscientist Mary Hynes named
research associate professor
Marc Tessier-Lavigne’s arrival at Rockefeller means the addition of not one, but
two active neuroscience research programs
to campus. This summer, Mary Hynes
— Dr. Tessier-Lavigne’s wife and a well
regarded neuroscientist in her own right
— will relocate from Stanford. As research
associate professor, she will investigate the
development of the key cells targeted by
Parkinson’s disease: dopaminergic neurons.
Dr. Hynes and colleagues were the
first to show that dopaminergic neurons
are induced by a molecule called Sonic
hedgehog. Her work led to a widely used
method involving a combination of this
and other molecules to derive dopaminergic neurons from embryonic stem cells.
Her research at Rockefeller will focus on
identifying molecular markers that distinguish the two types of dopaminergic nerve
cells, substantia nigra neurons, which
are involved in motor control and die in
Parkinson’s disease, and ventral tegmental
area neurons, which are part of a reward
pathway and are not as affected by the
disease. She wants to learn how to tease
substantia nigra neurons from embryonic
stem cells, and in better understanding
their development, inform possible treatments for Parkinson’s.
Substantia nigra and ventral tegmental
neurons are closely related and very difficult to parse, especially in early stages of
development. Her recent work has found
that certain axon guidance cues, molecules that direct the growth of neurons,
are expressed in striking patterns around
the developing dopaminergic neurons.
Using axon guidance receptor expression,
guidance cue responsiveness, in utero
tract-tracing, laser capture microdissection
and microchip array analysis, she hopes to
identify markers that distinguish the two
key populations of dopaminergic neurons.
The work could lead to methods for
specifically inducing and dissecting the development of substantia nigra neurons, and
a better understanding of guidance cue responsiveness could be used to improve the
targeting of transplanted neurons meant to
replace those killed off by Parkinson’s.
“Effective cell replacement therapy
will be assisted by the ability to generate

exactly the right kinds of dopaminergic
neurons. We hope that our work will help
accelerate this approach,” says Dr. Hynes.
At Stanford, Dr. Hynes leads a research
group in the department of biology. Like
her husband, she has experience both in
academia and industry. She graduated
from the University of Vermont in 1980
with a degree in psychology before taking
a fellowship to study electrophysiology at
Kyushu National University in Japan. Then
she joined an undergraduate mentor who
had moved to University of North Carolina
at one of the first major interdisciplinary
neurobiology doctoral programs in the U.S.
She earned her Ph.D. there in 1987 and
took a postdoctoral position at Columbia
University’s Center for Neurobiology and
Behavior, where she and Dr. Tessier-Lavigne
first met. In 1991, she joined biotechnology giant Genentech, initially as a postdoc,
and then on the scientific staff, eventually
becoming head of lab. In the late ’90s, she
moved to a biotech startup, where she was
associate director of neurobiology through
2002. She joined Stanford in 2003.
“I feel that my science has benefited
tremendously from working in both industry and academia,” Dr. Hynes says. “It is
the basic science that drives my research
program, but my time in industry has
helped me understand how to move basic
scientific discoveries towards applications
that might benefit patients.”
“Scientists from all over the city packed
a lecture room here last month to hear
Mary Hynes discuss her newest work on
cues that guide dopaminergic axons to
appropriate targets in the brain,” says Mike
Young, vice president for academic affairs.
“She also spoke about her stem cell work,
which has significant implications for cell
replacement therapies. Mary is a great
addition to the university’s neuroscience
research program and will have a valuable
place in the growth of stem cell science on
campus.”
Dr. Hynes was born in New York City
and grew up in Connecticut, and many of
her relatives still live in the region. In the
city, her great grandfather, Henry Heide,
founded Heide Candy Company, the maker
of Jujubes, Jujyfruits and Red Hot Dollars.

The Tessier-Lavigne-Hynes family

Marc Tessier-Lavigne and his wife, Mary Hynes, have three children. Christian (far right), 19, is
currently a sophomore at Princeton University; Kyle, 18, is a senior in high school and will attend
Dartmouth beginning this fall; and Ella, 12, is currently in seventh grade and will enroll in the
Dalton School on East 89th Street in September. Dr. Tessier-Lavigne, Dr. Hynes and Ella TessierLavigne will live in the President’s House beginning this summer with their two dogs, labradoodles named Cameo and Cinnamon, and two American Shorthair cats, a brother and sister named
Tom and Lily. This photo is from a 2009 vacation to Greece.

Understanding the brain (continued from page 1)
Discoveries of other chemoattractive
factors involved in neuronal guidance soon
followed, and over the years Dr. TessierLavigne’s lab has sought to identify the full
complement of cues guiding particular sets
of axons, as well as the intracellular pathways they trigger to signal directed motion.
Of course, the story gets more complicated. As an axon progresses along
its trajectory, its growth cone exhibits a
remarkable plasticity, changing its response
to guidance cues — losing responsiveness
to those that directed it over the previous
leg of its trajectory and acquiring responsiveness to those that will guide it over
the next leg. A major focus of Dr. TessierLavigne’s lab in recent years has been on
understanding the mechanisms that control
this plasticity and switching of growth
cone responses, and their relation to other
plastic changes, such as those occurring
after injury and in learning and memory.
The mechanisms that direct the formation of connections in the embryo also
regulate neuronal responses to injury in
the adult. While damaged axons in the

peripheral nervous system can regrow
and regenerate connections, in the central
nervous system — the brain and spinal
cord — they usually cannot, and paralysis
after spinal cord injury is often permanent.
Dr. Tessier-Lavigne’s lab has recently found
that some of the cues that guide axons in
the embryo contribute to blocking regeneration, and that inhibiting their actions
can help stimulate repair.
The mechanisms regulating the development of circuits are also relevant to neurodegenerative disease. In the embryo, too
many connections are initially formed and
many axons have to be eliminated through
a process of pruning or developmental
degeneration. Dr. Tessier-Lavigne’s lab has
shown that several of the cues that initially
guide axons are later responsible for triggering axon degeneration in the embryo,
and that there are important mechanistic
similarities between developmental degeneration and the degeneration that occurs
in diseases like Alzheimer’s, providing
potential therapeutic entry points for these
diseases.

Guiding neurons (continued from page 1)
says. “It’s a team-oriented environment where people are
working towards a defined goal — the development of
medicines — and you can get to see the fruits of your work
make their way through the clinic.”
He maintained relationships with several biotech firms
as he climbed the ranks in academia. He was promoted
to associate professor with tenure in 1995 and to professor in 1997, and he became a Howard Hughes Medical
Institute investigator beginning in 1994. In 2001 he moved
down the road to Stanford University, where he was named
Susan B. Ford Professor in the School of Humanities and
Sciences. But two years later, the draw of helping manage
the scientific portfolio of one of the biggest names in biotechnology — Genentech — proved too powerful to resist.
Genentech was the original biotechnology firm, a company established in 1976 to harness the power of recombinant DNA technology. Its founders, a venture capitalist
and a biochemist, joined forces at a time when neither
academia nor industry had much interest in one another.
Structured much like an academic institution, with semiindependent labs run by investigators and staffed with
postdocs and technicians, Genentech proved to be an enormous success. Its first product, synthetic insulin, was the
first genetically engineered human medicine to be approved
by the FDA. Today, Genentech is owned by Hoffmann-La
Roche and employs more than 11,000 people.
In 2003, Dr. Tessier-Lavigne took a leave of absence from
Stanford and set up shop at Genentech. The firm had just
had a string of commercial successes, and Dr. Tessier-Lavigne’s job was to help invest the new revenue into the next
generation of therapeutics. Leading an enormous research
organization — he started out directing about two-thirds
of Genentech’s scientific personnel and eventually ran all of
it — gave Dr. Tessier-Lavigne the chance to impact not just
the sliver of neuroscience he had staked out as an academic,
but also to influence how resources are allocated across
many areas of bioscience. What’s more, although he could
continue his basic research (Genentech, like Rockefeller, has

a tradition of executives maintaining active labs), he could
also be involved with translational work. He soon decided
that biotech suited him well, and made a long-term commitment to Genentech.
“Over the course of my career, my initial interest in
basic biological processes has grown into an equally strong
interest in disease processes and in the medical applications
of basic science,” Dr. Tessier-Lavigne says. “Genentech was
appealing because of its deep commitment to innovative research that has the potential to create breakthrough therapies for unmet medical needs. It also has a vibrant and
exciting scientific culture that fosters intellectual freedom.”
In fact, in many ways it’s a lot like Rockefeller. And
since Dr. Tessier-Lavigne has made a career out of straddling the fence between basic and translational science,
and has moved easily between the lab bench and executive
suite, coming to Rockefeller feels like a natural progression. Rockefeller, after all, was founded to focus on
translational medicine, pioneered the concept of a clinical
research hospital and has a long history of encouraging
scientists to straddle as many fences as they can.
“Basic and translational research depend on one another, and in many areas I believe we still don’t have the
basic insights on which clinical work can build — that’s
why places like Rockefeller are so important to our ability
to tackle disease,” Dr. Tessier-Lavigne says.
Dr. Tessier-Lavigne’s own field, neuroscience, is a fitting
example. Although he has continued to chip away at the
mysteries of neuronal guidance over the past decade, and
has made several important discoveries about the processes
of neuronal degeneration such as those that underlie Alzheimer’s and Parkinson’s diseases, there are still no cures
or reliable treatments. “Even now our understanding of
what goes wrong in the brain is limited, and it’s holding up
our ability to develop therapies,” he explains.
“Beyond disease, I remain as fascinated as ever by what
initially drew me to biology: the functioning of complex biological systems, from the operation of molecular

machines, to the morphogenesis of tissues and organs, to
the ability of the brain to perceive and store memories.
Rockefeller scientists remain at the forefront of research
into these fundamental processes — another reason I am so
excited to join this community.”
Dr. Tessier-Lavigne starts at Rockefeller on March 16. Several members of his existing Genentech research program will
move with him over the next few months, and he plans to ultimately staff his lab with a total of a dozen or so members —
postdocs, grad students and technical staff. It’s a size he feels
is both manageable and productive and will allow him to
keep his feet firmly planted in the process of making discoveries, his greatest joy. His family will move to New York once
the school year ends. In coming months, he plans to familiarize himself with the institution, tap into its diverse community
for counsel, and ultimately work with them to craft a strategy
for guiding Rockefeller through the coming years.
He sees his roles at Rockefeller, as at Genentech, as
those of leader and supportive player. “In both jobs, my
primary responsibility is to help recruit great people and
enable them to do great science,” says Dr. Tessier-Lavigne.
“In that regard, the skills I have developed in eight years
at Genentech are directly relevant to how I will operate as
president of Rockefeller. Together we will chart the course
for the university in the next five, ten, twenty years. Within
that framework, my aim will be to enable the university’s
faculty, students and research staff to be all that they can
be, to serve as mentor, colleague and problem-solver and
to make sure people have the resources they need to focus
on producing transformative science with a minimum of
distractions. Just as important, I will focus on making the
university a great place to work for all its members — scientists, administrators and support staff.
“That’s the formula that has led to the university’s
sustained success over its long history, and it’s what will
allow it to remain an international pioneer in fundamental
bioscience, in its application to human health and in training future scientific leaders.”

